AstraZeneca stock reacts as FDA grants accelerated approval for new breast cancer pill
Published on 09/06/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock (ISIN GB0009895292) closed at 162.62 USD on the New York Stock Exchange on September 4, 2026, down 1.30% from the previous session according to market data compiled by MarketBeat.
FDA nod for camizestrant adds to AstraZeneca’s oncology pipeline
On September 6, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s oral breast cancer therapy camizestrant in combination with a CDK4/6 inhibitor for ESR1-mutated, hormone receptor positive, HER2 negative metastatic breast cancer, with Guardant360 CDx serving as the companion diagnostic, as reported by Pharmanow.live. The report highlights the FDA’s accelerated approval decision for camizestrant.
The accelerated approval is based on clinical data indicating benefit in ESR1-mutated disease, even though an FDA oncology advisory committee earlier questioned whether the magnitude of benefit was meaningful for patients, as noted in coverage of the decision. Caliber describes the approval despite prior advisory committee concerns For investors, the key point is that camizestrant now has a regulatory foothold in the large US market, bolstering AstraZeneca’s oncology franchise, which already includes widely used therapies in lung and breast cancer.
Stock performance and recent trading range
AstraZeneca’s American depositary shares under the ticker AZN traded at 162.62 USD as of the close on September 4, 2026, with a daily decline of 2.15 USD or 1.30% compared with the prior close, according to MarketBeat data. MarketBeat provides the latest AZN price and daily change The same overview shows that AstraZeneca shares have experienced fluctuations around the 160 USD mark in recent sessions, reflecting a balance between optimism on oncology approvals and caution about valuation.
Price history data for AstraZeneca’s primary listing, compiled by Investing.com, indicate that the company’s London-traded shares closed at 12,006.0 in local quote units on September 4, 2026, down 1.15% from an opening level of 12,146.0, with intraday highs of 12,206.0 and lows of 11,986.0 and trading volume of 2.24 million. Investing.com lists the September 4, 2026 price history for AstraZeneca This intraday band of about 220.0 units between high and low underscores that the stock remains in a relatively tight trading range, with modest daily volatility rather than extreme swings.
Oncology focus and implications for revenue growth
Beyond camizestrant, AstraZeneca has recently reported a series of oncology milestones, including EU approvals for combinations such as Enhertu plus pertuzumab in HER2 positive breast cancer and new data for lung cancer therapy combinations, as summarized in recent news headlines aggregated by MarketBeat from multiple financial outlets. The same MarketBeat page lists multiple oncology regulatory and clinical updates These developments collectively point to an expanding product base in cancers where treatment durations and patient numbers can support significant revenue streams over time.
Real-world research into chronic diseases funded by AstraZeneca also underscores its strategic focus; for example, a late-breaking abstract presented at the European Respiratory Society Congress 2026 in Barcelona found that chronic obstructive pulmonary disease (COPD) carries a mortality burden that exceeds prostate and breast cancer and rivals heart failure, with funding support from AstraZeneca for COPD therapies, according to the American Journal of Managed Care. The AJMC article notes AstraZeneca’s funding of COPD research While not a direct revenue figure, such funding illustrates the company’s dual emphasis on oncology and respiratory diseases, both of which are large, long-duration markets that can underpin future sales growth.
More AstraZeneca stock coverage
For further company news and regulatory updates on AstraZeneca stock, including upcoming earnings commentary and additional pipeline developments, the topic page offers a broader overview.
Tagrisso as a flagship product in lung cancer
One of AstraZeneca’s flagship products is Tagrisso, a targeted therapy for epidermal growth factor receptor (EGFR) mutated non small cell lung cancer. Recent headlines indicate that AstraZeneca and HUTCHMED have reported Phase III results for a Tagrisso based combination with Orpathys in lung cancer patients, with coverage on financial portals referenced by MarketBeat. The news flow includes Phase III results for a Tagrisso-Orpathys combination Tagrisso has already become a standard of care in first line EGFR mutated lung cancer in many markets, and new combination data are important for defending and extending its clinical positioning against emerging competitors.
Given the high incidence of lung cancer globally and the need for prolonged treatment in metastatic disease, Tagrisso contributes materially to AstraZeneca’s oncology revenue. New trial readouts that show improved progression-free survival or overall survival compared with existing regimens can help sustain or grow these revenues in future periods, although exact revenue figures for the latest quarter are not specified in the most recent day filtered sources used here and would typically be detailed in AstraZeneca’s investor relations materials.
Stock valuation and investor perspective
From a valuation perspective, the current price of 162.62 USD for AstraZeneca stock on September 4, 2026 situates the shares within a zone where the market is balancing regulatory successes such as the camizestrant approval against concerns about whether incremental benefits in some trial settings justify premium pricing. The modest one day decline of 1.30% indicates that investors did not significantly re-rate the shares in immediate response to the latest FDA decision, suggesting that much of the oncology growth story may already be reflected in expectations.
For investors following AstraZeneca stock, the important questions over the coming quarters will center on how quickly camizestrant uptake materializes in the US, how Tagrisso and other established oncology drugs maintain or extend their leading positions, and how respiratory assets in COPD and asthma contribute to a more diversified earnings base. As new quarterly reports are released and updated guidance becomes available via AstraZeneca’s investor relations communications, the market will be able to quantify more precisely how regulatory and clinical milestones translate into top line and bottom line growth.
AstraZeneca key data
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Trading venue: NYSE (ADR), primary listing in London
- Price (as of September 4, 2026, 15:58): 162.62 USD
- Market capitalization: Market capitalization figure to be taken from real time market data as of the same date
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: FTSE 100
